Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 933-940

  Zhan, Na ^a   Dong, Wei Guo ^a   Tang, Yong Fei ^a   Wang, Ze Sheng ^a   Xiong, Cheng Long ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Esophageal squamous carcinoma; Fluorescence in situ hybridization; HER2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HER2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; CANCER GRADING; CANCER INVASION; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866297340     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9850-y     Document Type: Article

References (38)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049-53.
2. Mascarello JT, Brothman AR, Davison K, Dewald GW, Herrman M, McCandless D, Park JP, Persons DL, Rao KW, Schneider NR, Vance GH, Cooley LD. Proficiency testing for laboratories performing fluorescence in situ hybridization with chromosomespecific DNA probes. Arch Pathol Lab Med. 2002;126(12):1458.
3. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinoma: analysis of regional variation using the Cancer Incidence in FIVE Continents database. Int J Epidemiol. 2001; 30(6):1415-25.
4. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A. Status of c-ERBB-2 in gastric adenocarcinoma:a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer. 2002;98(6):833-7.
5. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Bery M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95(2):142-53.
6. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-9.
7. Penault-Llorca F, Vincent-Salomon A, Mathieu MC, Trillet- Lenoir V, Khayat D, Marty M. Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts). 2005;23:69s. Abstract 764.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82.
9. Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998; 34(6):791-808.
10. Sato-Kuwabara Y, Neves JI, Fregnani JHTG, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and Immunohistochemistry. BMC Cancer. 2009;9(6):1207-471.
11. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005;92(7):1253-60.
12. Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20(1):120-9.
13. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, Franklin W, Said S, Varella-Garcia M. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(2):111-9.
14. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, Korc M, Buchler MW. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg. 1999;23(10): 1010-8.
15. Suzuki H, Abo S, Kitamura M, Hashimoto M, Izumi K, Terada K, Sugiyama T. Gene amplification of int-2 and erbB in human esophageal cancer: relationship to clinicopathological variables. Cancer Invest. 1997;15(5):411-15.
16. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31(6): 637-43.
17. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-37.
18. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J, Alderson D. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol. 1997;23(1):30-5.
19. Lam KY, Tin L, Ma L. C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol. 1998;24(5): 431-5.
20. Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G. Bergqvist M: HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006;19(4):224-31.
21. Suo Z, Su W, Holm R, Nesland JM. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anticancer Res. 1995;15(6B):2797-8.
22. Suwanagool P, Parichatikanond P. Maeda S: Expression of c-erbB-2 oncoprotein in primary human tumors: an immunohistochemistry study. Asian Pac J Allergy Immunol. 1993;11(2): 119-22.
23. Dreilich M, Wanders A, Brattström D, Bergström S, Hesselius P, Wagenius G, Bergqvist M. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006;19(4):224-31.
24. Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmoller P, Gutjahr T, Kaufmann M, Henkel T, Ruschoff J. Central HER2 IHC and FISH analysis in a trastuzumab [Herceptin (R)] Phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol. 2008;61(1):89-94.
25. Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kollola A, Väyrynen A, Kärkkäinen P, Moskaluk C, El-Rifai W, Knuutila S. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer. 2004;109(4):548-53.
26. Wang S, Hossein Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L. Ashfaq R: Aneusomy 17 in breast cancer: Its role in Her2/neu protein expression and implication for clinical assessment of Her-2/neu status. Mod Pathol. 2002; 15(2):137-45.
27. Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol. 2001;25(9):1204-7.
28. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13(1):63-72.
29. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR. HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Dig Dis Sci. 2006;51(8):1371-9.
30. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall- cell lung cancer. J Natl Cancer Inst. 2005;97(9):643-55.
31. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive nonsmall-cell lung cancer patients. J Clin Oncol. 2005;23(22): 5007-18.
32. Tsuda H. HER-2 (c-erbB-2) test update: present status and problems. Br Cancer. 2006;13(3):236-48.
33. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer. 2001;37(Suppl 4):S16-22.
34. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol. 2002;3(3):137-44.
35. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22(6):1063-70.
36. Tuma RS. Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst. 2005;97(12):870-1.
37. Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97(4):494-501.
38. Gros SJ, Kurschat N, Dohrmann T, Reichelt U, Dancau AM, Peldschus K, Adam G, Hoffman RM, Izbicki JR, Kaifi JT. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther. 2010;9(7):2037-45.